Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy.

Published

Journal Article (Review)

Two decades of research into the role of immunosuppression and angiogenesis in tumor biology have revealed multiple links between the two. Vascular endothelial growth factor, originally thought to be solely involved in vascular growth and permeability, has emerged as a significant agent of immune tolerance in the tumor microenvironment. This review examines two major elements of this field: the research behind the role of vascular endothelial growth factor in immunosuppression, especially as pertains to dendritic cell function; and the subsequent research into the potential for using antiangiogenic therapy to both starve tumors by hypoxia and enhance the response of tumors to immunotherapy. Several strategies tested so far have yielded incomplete, yet promising, results.

Full Text

Duke Authors

Cited Authors

  • Johnson, BF; Clay, TM; Hobeika, AC; Lyerly, HK; Morse, MA

Published Date

  • April 2007

Published In

Volume / Issue

  • 7 / 4

Start / End Page

  • 449 - 460

PubMed ID

  • 17373897

Pubmed Central ID

  • 17373897

Electronic International Standard Serial Number (EISSN)

  • 1744-7682

Digital Object Identifier (DOI)

  • 10.1517/14712598.7.4.449

Language

  • eng

Conference Location

  • England